About this trial
In this study the investigators will assess both procoagulant and anticoagulant pathways using thrombin generation and platelet function tests; as well as neuronal ischemia using cell free DNA in all patients presenting with ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further investigated. As such the investigators aim to characterise the patient's coagulation profile before administration of any treatment. By assessing these pathways the investigators strive to detect specific markers to predict vital and functional outcome at 3 months in these patients. Finally the investigators may provide new pathophysiological insights in the course of disease following these events that can possibly improve future therapeutic strategies.
Eligibility criteria
Qualifiers
None
Disqualifiers
Refusal of participation by patient or legal representative
Traumatic intracranial (subdural, subarachnoid, epidural haematoma) bleeding
Patients receiving treatment with interference on coagulation (pro / anti) before first sampling: in this group of patients the coagulation assessment at presentation will be excluded, further lab sampling is performed according to protocol.
Patients categorized as having stroke mimic will be excluded from analysis afterwards
Trial design
Treatments tested in this trial
- blood sampling
Treatment groups
Sponsors and collaborators
Ziekenhuis Oost-Limburg
Lead sponsor
Synapse bv
Collaborator